Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Int J Vitam Nutr Res. 2021 Sep;91(5-6):649-658. doi: 10.1024/0300-9831/a000642. Epub 2020 Mar 9.
Trials on the effects of cholecalciferol supplementation in type 2 diabetes with chronic kidney disease patients were underexplored. Therefore, the aim of this study was to investigate the effects of two different doses of vitamin D supplementation on serum 25-hydroxyvitamin D [25(OH)D] concentrations and metabolic parameters in vitamin D-deficient Korean diabetes patients with chronic kidney disease. 92 patients completed this study: the placebo group (A, n = 33), the oral cholecalciferol 1,000 IU/day group (B, n = 34), or the single 200,000 IU injection group (C, n = 25, equivalent to 2,000 IU/day). 52% of the patients had less than 60 mL/min/1.73m of glomerular filtration rates. Laboratory test and pulse wave velocity were performed before and after supplementation. After 12 weeks, serum 25(OH)D concentrations of the patients who received vitamin D supplementation were significantly increased (A, -2.4 ± 1.2 ng/mL vs. B, 10.7 ± 1.2 ng/mL vs. C, 14.6 ± 1.7 ng/mL; < 0.001). In addition, the lipid profiles in the vitamin D injection group (C) showed a significant decrease in triglyceride and a rise in HDL cholesterol. However, the other parameters showed no differences. Our data indicated that two different doses and routes of vitamin D administration significantly and safely increased serum 25(OH)D concentrations in vitamin D-deficient diabetes patients with comorbid chronic kidney disease. In the group that received the higher vitamin D dose, the lipid profiles showed significant improvement, but there were no beneficial effects on other metabolic parameters.
关于补充胆钙化醇对 2 型糖尿病合并慢性肾脏病患者的影响的临床试验研究甚少。因此，本研究旨在探讨两种不同剂量的维生素 D 补充剂对维生素 D 缺乏的韩国 2 型糖尿病合并慢性肾脏病患者血清 25-羟维生素 D [25(OH)D]浓度和代谢参数的影响。92 例患者完成了这项研究：安慰剂组（A，n=33）、口服胆钙化醇 1000IU/天组（B，n=34）或单次 200000IU 注射组（C，n=25，相当于 2000IU/天）。52%的患者肾小球滤过率<60ml/min/1.73m。补充前后进行实验室检查和脉搏波速度检查。12 周后，接受维生素 D 补充的患者血清 25(OH)D 浓度显著升高（A：-2.4±1.2ng/ml；B：10.7±1.2ng/ml；C：14.6±1.7ng/ml；P<0.001）。此外，维生素 D 注射组（C）的血脂谱显示甘油三酯显著降低，HDL 胆固醇升高。然而，其他参数没有差异。我们的数据表明，两种不同剂量和途径的维生素 D 给药可显著且安全地增加合并慢性肾脏病的维生素 D 缺乏 2 型糖尿病患者的血清 25(OH)D 浓度。在接受较高维生素 D 剂量的组中，血脂谱显示出显著改善，但对其他代谢参数没有有益影响。
